Search PubMed⌕ Search

Biomedical subjects

M A Banks

Publications and source records attributed to M A Banks.

23 records · Page 2Linked to original sources
PubMed1988

Reversed-phase high-performance liquid chromatography technique for taurine quantitation.

Taurine (2-aminoethanesulfonic acid) was quantitated by reversed-phase chromatography on a C18 Resolve column using a linear gradient of 9-11% methanol in water. Glutamine was used as the internal standard. Pre-column derivatization of the amino acid with o-phthalaldehyde allowed the detection of as little as 0.1 pmol taurine. Dual ion-exchange column chromatography was employed to remove other amino acids and metabolic precursors of taurine from the samples. Cysteic acid and cysteine sulfinic acid did not interfere with taurine analysis by the high-performance liquid chromatographic method. For sample deproteinization, boiling and picric acid precipitation were used. Recovery of taurine averaged 93.5 +/- 5.0% (means +/- standard error of the mean) from standard solutions and was not affected by the method of deproteinization. Using this procedure, plasma taurine concentrations for the rat and chick were determined to be 100.7 +/- 13.1 microM and 108.0 +/- 0.3 microM, respectively. Recovery of taurine from plasma samples averaged 97.2 +/- 4.7%.

Animals↗
PubMed1982

Products of cultured neuroglial cells. III. Release of an 85,000 molecular weight glycoprotein by C6 glioma cells in vitro.

With [3H]fucose as a marker, C6 glioma cells in culture released an 85,000 molecular weight molecule into the medium as the major extracellular glycoprotein. The quantity and extracellular/cytoplasmic ratio of this glycoprotein suggest that its cellular processing is different from that of five other released glycoproteins of molecular weights 55,000, 115,000, 130,000, 150,000, and 170,000. Nearly 40% of newly synthesized glycoproteins in the cells was released into the culture medium. Major glycoproteins retained by the cells migrated electrophoretically to molecular weight positions of 82,000, 110,000, 120,000, 140,000, and 160,000, and approximately one-third of these returned glycoproteins were labile to trypsinization. Both synthesis and release of these macromolecules were inhibited more than 95% with cycloheximide treatment, demonstrating that nearly all fucosylation was linked to protein synthesis. Since 40% of all glycoproteins was released under conditions of more than 99% cellular viability, it is likely that these extracellular glycoproteins are physiological products of membrane turnover and secretion, but not of cell lysis. The results provide a basis for the further study of glial differentiation and of shed glioma antigens.

Animals↗
PubMed1981

Biosynthesized products of cultured neuroglial cells: I. Selective release of proteins by cells from human astrocytomas.

The proteins synthesized and released by human astrocytoma cells cultured with radiolabeled amino acids were analyzed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate and by trichloracetic acid precipitation. A select group of extracellular proteins was released from the astrocytomas. The most abundant extracellular proteins were at least 250,000 daltons. Five other major proteins (P 175, P 125, P 60, P 47, and P 40) were 175,000, 125,000, 60,000, 47,000, and 40,000 daltons, respectively. The complement of proteins retained by the cells was considerably more complex than those released. Clinical efforts to enhance the immunologic response directed against human astrocytomas must distinguish between extracellular and retained antigens. The pattern of proteins released by gliomas might be diagnostically useful if present in cerebrospinal fluid or serum.

Amino Acids↗
PubMedDate not supplied

Home infusion of intravenous immunoglobulin.

Intravenous immunoglobulin (IGIV) is being used extensively in the home-care setting to treat patients with a wide variety of disorders. This therapy can be managed more effectively when the patient and/or caregiver have been educated regarding the therapy. In this article, a therapy education plan, policies, and procedures that address the key components of providing IGIV treatments in the home-care setting will be presented. Instructional information is presented in "patient-friendly terms" that can be readily applied to the nursing care plan. This plan will be applicable for patients who will become independent with the administration of their IGIV as well as for those who will have their IGIV administered by the home-care nurse.

Home Infusion Therapy↗